![Krishna Vaddi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 21 M $ al 31/08/2026
El Dr. Krishna Vaddi es director general y consejero de Prelude Therapeutics, Inc. Forma parte del Consejo de Administración de Prelude Therapeutics, Inc. El Dr. Vaddi trabajó anteriormente como Director Ejecutivo de Orsenix LLC y como Director Ejecutivo y Vicepresidente del Grupo de Incyte Corp. Se licenció en la Universidad Agrícola Acharya N. G. Ranga y se doctoró en la Universidad de Florida.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 27/04/2026 | 3.669.054 ( 5,64 % ) | 21 M $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Fundador | 01/01/2016 |
| Empresas | Cargo | Fin |
|---|---|---|
Orsenix LLC
 Orsenix LLC BiotechnologyHealth Technology Operates as a clinical-stage biotech company developing a novel oral form of arsenic trioxide to treat acute promyelocytic leukemia | Director Ejecutivo | 01/06/2016 |
| INCYTE CORPORATION | Director/Miembro de la Junta | 01/06/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
University of Florida
 University of Florida Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Acharya N. G. Ranga Agricultural University
 Acharya N. G. Ranga Agricultural University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prelude Therapeutics, Inc.
 Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Orsenix LLC
Orsenix LLC BiotechnologyHealth Technology Operates as a clinical-stage biotech company developing a novel oral form of arsenic trioxide to treat acute promyelocytic leukemia | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
